Cargando…

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

BACKGROUND: In cardiovascular outcome trials, the sodium glucose cotransporter 2 inhibitor empagliflozin and glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide caused similar reductions in major adverse cardiac events (MACE). We compared clinical outcomes in routine clinical care. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomsen, Reimar W., Knudsen, Jakob S., Kahlert, Johnny, Baggesen, Lisbeth M., Lajer, Maria, Holmgaard, Pia H., Vedin, Ola, Ustyugova, Anastasia, Sørensen, Henrik T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483550/ https://www.ncbi.nlm.nih.gov/pubmed/34032121 http://dx.doi.org/10.1161/JAHA.120.019356

Ejemplares similares

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2022)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
por: Ramos, Mafalda, et al.
Publicado: (2019)

Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study
por: Kristensen, Frederik Pagh Bredahl, et al.
Publicado: (2023)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
por: Ramos, Mafalda, et al.
Publicado: (2020)

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2022)

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Healthcare resource utilization in patients treated with empagliflozin in East Asia
por: Sheu, Wayne H‐H, et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Using registries to identify type 2 diabetes patients
por: Thomsen, Reimar W, et al.
Publicado: (2014)

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
por: Nakaguchi, Hirotatsu, et al.
Publicado: (2020)

Female resistance to pneumonia identifies lung macrophage nitric oxide synthase-3 as a therapeutic target
por: Yang, Zhiping, et al.
Publicado: (2014)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study
por: Mor, Anil, et al.
Publicado: (2016)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
por: Anderson, John E., et al.
Publicado: (2016)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
por: Funck, Kristian L., et al.
Publicado: (2020)

Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997–2017: Time trends in incidence and HbA(1c) and glucose‐lowering drug use before and after hypoglycaemia
por: Bengtsen, Mads Bisgaard, et al.
Publicado: (2021)

Short-term mortality after perforated or bleeding peptic ulcer among elderly patients: a population-based cohort study
por: Christensen, Steffen, et al.
Publicado: (2007)

Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
por: Bisgaard, Line S., et al.
Publicado: (2016)

Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
por: Li, Qian, et al.
Publicado: (2014)

Hospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality
por: Schmidt, Sigrun A. J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kflvh6in4eji96gqhrnbon9dig